These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 21989766)
1. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210 [TBL] [Abstract][Full Text] [Related]
5. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944 [TBL] [Abstract][Full Text] [Related]
7. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Okamoto I; Shimizu T; Miyazaki M; Tsurutani J; Ichikawa Y; Terashima M; Takeda M; Fumita S; Ohki E; Kimura N; Hashimoto J; Nakagawa K Invest New Drugs; 2012 Apr; 30(2):639-46. PubMed ID: 20960028 [TBL] [Abstract][Full Text] [Related]
8. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950 [TBL] [Abstract][Full Text] [Related]
10. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Reck M; Frickhofen N; Cedres S; Gatzemeier U; Heigener D; Fuhr HG; Thall A; Lanzalone S; Stephenson P; Ruiz-Garcia A; Chao R; Felip E Lung Cancer; 2010 Nov; 70(2):180-7. PubMed ID: 20188433 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559 [TBL] [Abstract][Full Text] [Related]
13. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863 [TBL] [Abstract][Full Text] [Related]
14. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087 [TBL] [Abstract][Full Text] [Related]
17. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486 [TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057 [TBL] [Abstract][Full Text] [Related]
20. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]